Eli Lilly and Company $LLY Shares Purchased by Richard C. Young & CO. LTD.

Richard C. Young & CO. LTD. lifted its stake in Eli Lilly and Company (NYSE:LLY) by 6.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,276 shares of the company’s stock after purchasing an additional 1,091 shares during the period. Eli Lilly and Company makes up 1.9% of Richard C. Young & CO. LTD.’s investment portfolio, making the stock its 17th largest holding. Richard C. Young & CO. LTD.’s holdings in Eli Lilly and Company were worth $20,715,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. AEGON ASSET MANAGEMENT UK Plc lifted its stake in shares of Eli Lilly and Company by 35.1% in the fourth quarter. AEGON ASSET MANAGEMENT UK Plc now owns 67,329 shares of the company’s stock valued at $72,391,000 after purchasing an additional 17,475 shares during the period. Vanguard Group Inc. lifted its stake in shares of Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after purchasing an additional 1,006,885 shares during the period. First Interstate Bank acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $247,000. Munich Reinsurance Co Stock Corp in Munich lifted its stake in shares of Eli Lilly and Company by 1.3% in the fourth quarter. Munich Reinsurance Co Stock Corp in Munich now owns 74,208 shares of the company’s stock valued at $80,126,000 after purchasing an additional 942 shares during the period. Finally, Pinion Investment Advisors LLC raised its position in Eli Lilly and Company by 157.0% during the fourth quarter. Pinion Investment Advisors LLC now owns 766 shares of the company’s stock worth $823,000 after acquiring an additional 468 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Large AI gene?editing partnership with Profluent (up to $2.25B) broadens Lilly’s digital biology and next?generation genetic medicine pipeline, a long?term growth and valuation positive. Read More.
• Positive Sentiment: Acquisition of Ajax Therapeutics (up to $2.3B) adds a JAK2 myelofibrosis program and deepens oncology exposure — complementary to recent M&A and supports analyst bullishness. Read More.
• Positive Sentiment: Analyst support and price?target moves (e.g., Guggenheim raise) reflect confidence that acquisitions plus pipeline execution justify upside vs. the pullback. This can underpin buying interest if Q1 execution meets expectations. Read More.
• Neutral Sentiment: Wall Street forecasts strong Q1 revenue growth (~36–37%) and investors expect pipeline commentary; earnings results and management commentary will be the immediate catalyst for intraday moves. Read More.
• Neutral Sentiment: Options and trader models imply sizable post?earnings volatility — the report could drive a sharp move either way, so risk around the print is elevated. Read More.
• Negative Sentiment: Early launch data show Foundayo prescriptions lagging a Novo rival and social chatter flags a slow oral GLP?1 rollout; weaker uptake puts short?term pressure on growth expectations for obesity franchise. Read More.
• Negative Sentiment: Canada approved cheaper generic weight?loss drugs, highlighting accelerating competitive and pricing risks in the GLP?1 market that could weigh on sales mix and margins over time. Read More.
• Negative Sentiment: Notable insider selling activity and some fund/portfolio churn reported recently; heavy sales can be perceived negatively by sentiment?driven investors ahead of the quarter. Read More.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $851.65 on Thursday. The firm has a 50 day simple moving average of $948.77 and a 200-day simple moving average of $985.31. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The firm has a market cap of $804.65 billion, a PE ratio of 37.11, a P/E/G ratio of 1.03 and a beta of 0.51. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 33.9 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Cantor Fitzgerald lifted their target price on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Barclays started coverage on shares of Eli Lilly and Company in a research report on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 target price for the company. Royal Bank Of Canada started coverage on Eli Lilly and Company in a research report on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 price target for the company. Weiss Ratings reissued a “buy (b)” rating on shares of Eli Lilly and Company in a research report on Friday, March 27th. Finally, Wells Fargo & Company raised their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,216.52.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.